Skip to main content
Equibles
BOLT logo

BOLT · Bolt Biotherapeutics, Inc. · Metrics

Track BOLT — free

Use BOLT with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research BOLT.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$3.45 -0.06 (-1.71%) At close · Oct 2
Rebalance outlook locked
Going-concern doubt — flagged Aug 11, 2026

Substantial doubt about the company's ability to continue as a going concern.

“The Company believes that this raises substantial doubt about its ability to continue as a going concern within one year after the issuance of the unaudited condensed consolidated financial statements.”
View the 10-Q filed Aug 11, 2026
Market Cap
$6.93M
Shares
1.93M
Volume · Oct 2 885 Avg daily vol (3M) 25.46K

BOLT metrics

62 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$3.45
Market cap
$6.93M

Price action

20 metrics
Price change (1W)
-3.6%
Price change (30D)
-11.5%
Price change (3M)
-14.8%
Price change (6M)
-19.6%
Price change (YTD)
-36.9%
Price change (1Y)
-30.4%
Trailing year
Price change (5Y)
—
52-week high
$7.09
52-week low
$3.18
Change from 52-week high
-51.3%
Change from 52-week low
+8.6%
Annualized volatility
75.2%
Annualized volatility (3M)
71.4%
Beta
0.7
RSI (14D)
42.9
Price vs SMA 50
-7.5%
Price vs SMA 200
-24.9%
Avg volume (3M)
25,461
Relative volume
0.0
Average dollar volume
$94,070

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
1.93M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
1.5×
reciprocal yield 67.8%
P / book
0.5
reciprocal yield 182.3%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-414.4%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2025-08-14

Profitability

9 metrics
Gross margin
—
Operating margin
-654.5%
Trailing 12 months
Net margin
-611.5%
Gross profit (TTM)
—
Operating profit (TTM)
−$30.76M
Net income (TTM)
−$28.74M
Trailing 12 months
Diluted EPS (TTM)
$-16.51
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$13.80

Growth

11 metrics
Revenue growth YoY
-99.7%
Year over year
Net income growth YoY
—
Revenue (TTM)
$4.70M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
-11.8%
Year over year · fewer shares
Revenue CAGR (3Y)
+10.3%
Revenue CAGR (5Y)
+101.6%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-227.4%
Return on assets
-71.2%
Debt / equity
—
Current ratio
2.6
EBITDA (TTM)
−$29.84M
Free cash flow (TTM)
—
Quick ratio
2.6
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$17.60M
Latest balance sheet
Cash & equivalents
$12.86M
Total assets
$40.34M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$31.45M
Capital expenditures (TTM)
$85,000
R&D (TTM)
$21.50M
SG&A (TTM)
—
Stock compensation (TTM)
$2.54M
R&D / revenue
457.5%
Stock compensation / revenue
54.1%

Ownership (13F)

3 metrics
13F filers
23
13F filer change QoQ
-1
Institutional ownership
31.0%

Short interest

3 metrics
Short interest
1.0%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
43 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$128,281
Insider-sentiment score
24 / 100

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1641281 CUSIP 097702203 Visit website Investor relations